About Us
Cornerstone Pharmaceuticals, Inc. is committed to changing the way cancer is treated through the discovery and development of innovative drug therapies that target distinctive metabolic processes of cancer cells.
Our research into cancer metabolism has led to the discovery of novel, first-in-class drugs and drug delivery technologies that have the potential to revolutionize cancer treatment.
- CPI-613, our lead drug from our Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is currently in Phase I/II clinical trials.
- Emulsiphan, our novel drug delivery technology, is designed to dramatically improve the safety and usefulness of existing and novel cancer therapies.
Our platforms are market driven and combine novel drug and formulation strategies that target metabolic features of cancer cells that are characteristic of diverse tumor types and are designed to provide the safest and most effective treatments for multiple types of cancer.
Cornerstone is currently conducting human clinical trials of its lead drug, CPI-613, from a pharmacologically novel class of drugs that target key enzymes involved in cancer cell metabolism. Cornerstone is also advancing the development of its proprietary nanoemulsion drug delivery system. The company’s founding members, management and scientific advisory team include preeminent scientists focused on cancer cell metabolism, cancer research and drug development.
